In cancer cells, these events are often associated with deletions directly within the FRA3B region, centering on exon 5 of FHIT. A high frequency of heterozygous and homozygous deletions with breakpoints within the fragile site region of FHIT has been detected in large number of cancers and cancer cell lines [5, 18–21]. This evidence concerns the gene FHIT and cancer.